Raphael Dolin, M.D.

Education

• Harvard College, Cambridge, MA, B.A., 1963 (History, magna cum laude)
• Harvard Medical School, Boston, MA, M.D., 1967 (Medicine, cum laude)
• Training
  Resident, Department of Medicine, Boston City Hospital, 1967-1969 (Internal Medicine)
• Research Associate, Laboratory of Infectious Diseases, NIAID, Bethesda, MD, 1969-1972
• Fellow, Infectious Diseases, Channing Laboratory, Boston, MA, 1972-1973 (Infectious Diseases)

Appointments

• 1973-1974: Senior Investigator, Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD
• 1974-1978: Head, Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy & Infectious Diseases, National Institutes Diseases, National Institutes of Health, Bethesda, MD
• 1979-1982: Professor of Medicine, University of Vermont College of Medicine, Burlington, VT
• 1979-1982: Director, Infectious Diseases Unit, Department of Medicine, University of Vermont College of Medicine, Burlington, VT
• 1982-1998: Professor of Microbiology and Immunology, University of Rochester School of Medicine & Dentistry, Rochester, NY
• 1982-1991: Professor of Medicine; Head, Infectious Diseases Unit, University of Rochester School of Medicine & Dentistry

1991-1994: Director, Clinical Research Center, University of Rochester School of Medicine and Dentistry

1991-1998: Charles A. Dewey Professor & Chairman, Department of Medicine, University of Rochester School of Medicine & Dentistry

1998-1999: Professor of Medicine, Harvard Medical School, Boston, MA

1998-2003: Dean for Clinical Programs, Harvard Medical School, Boston, MA

1999-2001: Maxwell Finland Professor of Medicine, Harvard Medical School, Boston MA

2001- : Maxwell Finland Professor of Medicine (Microbiology and Molecular Genetics), Harvard Medical School, Beth Israel Deaconess Medical Center and Brigham and Women’s Hospital, Boston, MA

2003-2008: Dean for Academic and Clinical Programs, Harvard Medical School, Boston, MA

Publications

• Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector. J. Infect. Dis. 2018; 218:633-644. [Article]


• Baden LR, Karita E, Mutua G, Bekker LG, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S, Laher F, Innes C, Seaman MS, Cohen YZ, Peter L, Frahm N, McElrath MJ, Hayes P, Swann E, Grunenberg N, Grazia-Pau M, Weijtens M, Sadoff J, Dally L, Lombardo A, Gilmour J, Cox J, Dolin R, Fast P, Barouch DH, Laufer DS; B003-IPCAVD004-HVTN091 Study Group. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann. Intern. Med. 2016; 164:313-322. [Article]


• Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN (Dolin R). Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis. 2016 Feb 15;213(4):541-50. PMCID: PMC4721914. [Article]


• Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J. Infect. Dis. 2015; 211:518-528. [Article]


• Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH. First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 (IPCAVD 002). J Infect Dis. 2014 Oct;210(7):1052-61. PMCID: PMC4168302. [Article]


• Goepfert PA, Elizaga ML, Seaton KE, et al.; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network (Dolin R). Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. J Infect Dis. 2014 July;210(1):99-110. PMCID: PMC4072895. [Article]


• Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis. 2013; 207:248-256. [Article]


• Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 2013; 207:240-247. [Article]


• Cohen YZ, Dolin R. Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines. 2013 Sep;1(3)99-112. PMCID: PMC3967667. [Article]


• Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR. Safety and immongenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J. Infect. Dis. 2013, 207(12):1888-97. [Article]